Inventor · disambiguated record
Ji-Feng Liu
Also filed as: LIU JI · LIU JI-FENG
3 granted patents·6 pending applications·16 citations·filing 2008–2021
65Inventor score
Top patents by PatentIndex Score
9 records- 0189US8299106B2Compositions of kinase inhibitors and their use for treatment of cancer and other diseases related to kinasesLI CHIANG JIA·Filed 2008·Granted Oct 30, 2012·12 cites·6 claims
- 0280US9187454B2Inhibitors of kinases and cancer stem cells, and methods of preparation and use thereofBOSTON BIOMEDICAL INC·Filed 2014·Granted Nov 17, 2015·4 cites·18 claims
- 0362US9725444B2Compositions of kinase inhibitors and their use for treatment of cancer and other diseases related to kinasesBOSTON BIOMEDICAL INC·Filed 2014·Granted Aug 8, 2017·0 cites·18 claims
- 0462US2019248781A1Compositions of kinase inhibitors and their use for treatment of cancer and other diseases related to kinasesBOSTON BIOMEDICAL INC·Filed 2018·Application pending·0 cites
- 0559US2018022743A1Compositions of kinase inhibitors and their use for treatment of cancer and other diseases related to kinasesBOSTON BIOMEDICAL INC·Filed 2017·Application pending·0 cites
- 0658US2012321622A1Compositions of Kinase Inhibitors and Their Use for Treatment of Cancer and Other Diseases Related to KinasesLI CHIANG JIA·Filed 2012·Application pending·0 cites
- 0748US2021318315A1Ultra-high-throughput microfluidic enzyme screening platform for enzyme developmentNAT UNIV SINGAPORE·Filed 2021·Application pending·0 cites
- 0848US2016031888A13-(aryl or heteroaryl) methyleneindolin-2-one derivatives as inhibitors of cancer stem cell pathway kinases for the treatment of cancerBOSTON BIOMEDICAL INC·Filed 2014·Application pending·0 cites
- 0947US2019241569A13-(aryl or heteroaryl) methyleneindolin-2-one derivatives as inhibitors of cancer stem cell pathway kinases for the treatment of cancerBOSTON BIOMEDICAL INC·Filed 2018·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Ji-Feng Liu files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →